Mounjaro®
Starting from £179.99/mo
Start journey Learn moreSemaglutide tablets for weight loss are taken once daily, every day, on a fixed schedule. The licensed dose starts at 1.5 mg and escalates through 4 mg and 9 mg to a 25 mg maintenance dose, with at least four weeks at each level before moving up. These are prescription-only tablets, and a prescriber determines which stage of the schedule is right for you.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
You have set your alarm five minutes earlier than usual. Before the kettle goes on, before breakfast, before your morning coffee, you take one semaglutide tablet with a small amount of plain water (up to around 120 ml). Then you wait. At least 30 minutes must pass before you eat, drink anything other than water, or take other oral medicines. That window is not arbitrary: oral semaglutide relies on an absorption enhancer called SNAC that works only in a fasted stomach, so even a cup of tea too soon can reduce how much of the medicine gets into your system.
The timing of that morning dose is the single most practical thing to get right. Swallow the tablet whole, do not crush or split it. Once it is down and your 30 minutes are up, the rest of your day carries on as normal.
One detail worth knowing: because timing is so critical, building a small cue into your morning routine (putting the pack next to the bathroom sink, or setting a phone reminder) makes adherence considerably easier over weeks and months. The mechanism behind the tablet rewards consistency; erratic timing undermines it.
The licensed weight-management tablet (approved by the MHRA on 11 June 2026 as the first oral GLP-1 medicine for weight loss in the UK) follows a stepwise escalation: 1.5 mg for the first month, then 4 mg, then 9 mg, then the 25 mg maintenance dose. A minimum of four weeks passes at each step. Moving up too quickly increases the risk of gastrointestinal side effects; the gradual ramp exists to let your body adjust.
People who are already established on the 2.4 mg weekly semaglutide injection may be able to move directly to the 25 mg tablet, but that transition is a clinical decision made with your prescriber, not something to self-manage. Trial data from the OASIS 4 study reported an average weight loss of around 13.6% over 64 weeks (and roughly 16.6% among participants who adhered fully to treatment throughout); those figures reflect the full maintenance dose, not the early weeks on 1.5 mg or 4 mg.
If you want to understand what to expect from the tablet over time, the dose stage you are at matters as much as the medicine itself. Your prescriber tracks your progress at each review before authorising a dose increase, that clinical checkpoint is part of how a regulated service works.
Life is not always a spotless morning routine. If you forget your tablet, the MHRA-approved Patient Information Leaflet (the definitive reference, available on the Electronic Medicines Compendium) sets out exactly what to do, and your prescriber's guidance takes precedence over any general summary. As a factual description of the licensed approach: if more than 12 hours remain before your next scheduled dose, you may take the missed tablet with a sip of plain water on an empty stomach, observe the 30-minute wait, and then return to your usual schedule. If fewer than 12 hours remain, skip it and continue from the next day. Do not double up.
For precise missed-dose instructions (particularly if you are changing doses or have taken two tablets close together) the Patient Information Leaflet is the right document, and your prescriber or our aftercare team can clarify. The general FAQs on this site cover common practical questions our clinical team hears regularly.
For many people the daily tablet is a more manageable routine than a weekly injection, particularly for those who travel frequently or feel apprehensive about self-injection. There is no cold chain to manage, the tablets sit at room temperature, making them straightforward to take on holiday or to keep in a desk drawer.
The trade-off is that the tablet demands more attention to timing. The injection is once a week on any day you choose; the tablet is every single morning, with a strict pre-food wait. Neither approach is objectively better, it depends on your routine, your preferences, and your clinical picture. An overview of how the oral tablet compares to other semaglutide formats can help you think it through, and the full Wegovy tablet guide covers eligibility and the approval background in more detail.
For context on what private treatment costs, the Wegovy tablet cost page sets out what is included in a private prescription service. These are prescription-only medicines, and clinical assessment by a qualified prescriber is required before any treatment begins, that is not a formality; it is what keeps the medicine safe and appropriate for you specifically. The NHS does not yet fund the Wegovy tablet; a NICE appraisal would be required first, as confirmed by the MHRA's approval announcement for oral semaglutide.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.